Similar articles

• An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B.

  Jansen L, de Niet A, Makowska Z, Dill MT, van Dort KA, Terpstra V, Bart Takkenberg R, Janssen HL, Heim MH, Kootstra NA, Reesink HW. Jansen L, et al. Liver Int. 2015 Jul;35(7):1824-32. doi: 10.1111/liv.12768. Epub 2015 Jan 21. Liver Int. 2015. PMID: 25533046 Clinical Trial.
• [Interferon therapy for chronic hepatitis B].

  Hige S, Sho T, Nakanishi M, Chuma M. Hige S, et al. Nihon Rinsho. 2011 May;69 Suppl 4:481-5. Nihon Rinsho. 2011. PMID: 22096965 Review. Japanese. No abstract available.
• Peginterferon therapy for chronic hepatitis B: one size fits all?

  Chan HL. Chan HL. Gut. 2013 Feb;62(2):185-7. doi: 10.1136/gutjnl-2012-303291. Epub 2012 Sep 1. Gut. 2013. PMID: 22942237 No abstract available.
• Focus.

  Shouval D. Shouval D. J Hepatol. 2013 Dec;59(6):1151-2. doi: 10.1016/j.jhep.2013.09.005. Epub 2013 Sep 7. J Hepatol. 2013. PMID: 24021425 No abstract available.
• [PEG-interferons: significance for the treatment of viral hepatitis B and C].

  Wedemeyer H, Cornberg M, Manns MP. Wedemeyer H, et al. Dtsch Med Wochenschr. 2001 Jun 1;126 Suppl 1:S68-75. doi: 10.1055/s-2001-14495. Dtsch Med Wochenschr. 2001. PMID: 11450618 Review. German. No abstract available.